Changes in body mass index and clinical outcomes after initiation of contemporary antiretroviral regimens

Wendy P Bannister, T Christopher Mast, Stéphane de Wit, Jan Gerstoft, Lothar Wiese, Ana Milinkovic, Vesna Hadziosmanovic, Amanda Clarke, Line D Rasmussen, Karine Lacombe, Philipp Schommers, Therese Staub, Alexandra Zagalo, Joseba J Portu, Luba Tau, Alexandra Calmy, Matthias Cavassini, Martin Gisinger, Elena Borodulina, Amanda MocroftJoanne Reekie, Lars Peters

Research output: Contribution to journalJournal articleResearchpeer-review


BACKGROUND: Weight gain is becoming increasingly prevalent amongst people with HIV (PWH) receiving contemporary antiretroviral treatment. We investigated BMI changes and clinical impact in a large prospective observational study. METHODS: PWH aged ≥18 years were included who started a new antiretroviral (baseline) during 2010-2019 with baseline and ≥1 follow-up BMI assessment available. Rates of clinical outcomes (cardiovascular disease [CVD], malignancies, diabetes mellitus [DM] and all-cause mortality) were analysed using Poisson regression to assess effect of time-updated BMI changes (>1 kg/m 2 decrease, ±1 kg/m 2 stable, >1 kg/m 2 increase), lagged by 1-year to reduce reverse causality. Analyses were adjusted for baseline BMI plus key confounders including antiretroviral exposure. RESULTS: 6721 PWH were included; 72.3% were male, median age 48 years (interquartile range [IQR] 40-55). At baseline, 8.4% were antiretroviral-naive, and 5.0% were underweight, 59.7% healthy weight, 27.5% overweight, and 7.8% were living with obesity. There was an 8.2% increase in proportion of overweight and 4.8% in obesity over the study period (median follow-up 4.4 years [IQR 2.6-6.7]).100 CVDs, 149 malignancies, 144 DMs, and 257 deaths were observed with incidence rates 4.4, 6.8, 6.6, 10.6 per 1000 person-years of follow-up, respectively. Compared to stable BMI, >1 kg/m 2 increase was associated with increased risk of DM (adjusted incidence rate ratio [IRR]: 1.96, 95% confidence interval [CI]: 1.36-2.80) and >1 kg/m 2 decrease with increased risk of death (adjusted IRR: 2.33, 95% CI: 1.73-3.13). No significant associations were observed between BMI changes and CVD or malignancies. CONCLUSIONS: A BMI increase was associated with DM and a decrease associated with death.

Original languageEnglish
JournalAIDS (London, England)
Issue number15
Pages (from-to)2107-2119
Publication statusPublished - 1. Dec 2022


  • Adolescent
  • Adult
  • Anti-Retroviral Agents/therapeutic use
  • Body Mass Index
  • Cardiovascular Diseases/complications
  • Diabetes Mellitus/epidemiology
  • Female
  • HIV Infections/complications
  • Humans
  • Male
  • Middle Aged
  • Neoplasms/drug therapy
  • Obesity/drug therapy
  • Overweight/complications
  • Risk Factors
  • cardiovascular disease
  • malignancy
  • antiretroviral therapy
  • body mass index
  • diabetes mellitus
  • mortality


Dive into the research topics of 'Changes in body mass index and clinical outcomes after initiation of contemporary antiretroviral regimens'. Together they form a unique fingerprint.

Cite this